Additionally, the 36-month beta value for NLSP is -0.53. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NLSP is 28.57M and currently, short sellers hold a 18.08% ratio of that float. The average trading volume of NLSP on July 18, 2024 was 10.03M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NLSP) stock’s latest price update
NLS Pharmaceutics Ltd (NASDAQ: NLSP)’s stock price has soared by 4.57 in relation to previous closing price of 0.21. Nevertheless, the company has seen a gain of 7.12% in its stock price over the last five trading days. accesswire.com reported 2024-06-28 that ZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
NLSP’s Market Performance
NLS Pharmaceutics Ltd (NLSP) has experienced a 7.12% rise in stock performance for the past week, with a 48.08% rise in the past month, and a 65.11% rise in the past quarter. The volatility ratio for the week is 8.93%, and the volatility levels for the past 30 days are at 23.00% for NLSP. The simple moving average for the past 20 days is 9.87% for NLSP’s stock, with a -40.33% simple moving average for the past 200 days.
NLSP Trading at 31.33% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.78% of loss for the given period.
Volatility was left at 23.00%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares sank -18.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.76% upper at present.
During the last 5 trading sessions, NLSP rose by +7.32%, which changed the moving average for the period of 200-days by -68.57% in comparison to the 20-day moving average, which settled at $0.1974. In addition, NLS Pharmaceutics Ltd saw -62.77% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 1.94.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -5.93. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -81.34.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In conclusion, NLS Pharmaceutics Ltd (NLSP) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.